UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Pharmacokinetic Study of Levetiracetam in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old
Phase 2
Completed
- Conditions
- Epilepsy
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 13
- Registration Number
- NCT00544050
Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis
Phase 4
Completed
- Conditions
- Rhinitis, Allergic, Seasonal
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 94
- Registration Number
- NCT00542607
Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 33
- Registration Number
- NCT00535392
Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 322
- Registration Number
- NCT00530855
- Locations
- 🇺🇸
137, Waldorf, Maryland, United States
🇺🇸094, Doral, Florida, United States
🇺🇸029, Scarborough, Maine, United States
Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis
Phase 3
Completed
- Conditions
- RhinitisAllergicPerennial
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 71
- Registration Number
- NCT00524836
To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis
Phase 3
Completed
- Conditions
- AllergicRhinitisSeasonal
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 67
- Registration Number
- NCT00525278
Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria
Phase 3
Completed
- Conditions
- Urticaria
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 134
- Registration Number
- NCT00525382
Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy
Completed
- Conditions
- Epilepsy
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2012-05-30
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 400
- Registration Number
- NCT00522522
- Locations
- 🇺🇸
UCB Pharma, Smyrna, Georgia, United States
Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 514
- Registration Number
- NCT00522379
Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR
Not Applicable
Completed
- Conditions
- Rhinitis, Allergic, Seasonal
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 459
- Registration Number
- NCT00521040
© Copyright 2025. All Rights Reserved by MedPath